Gut Health and the Microbiome

Inflammatory Bowel Disease (IBD) is a group of debilitating disorders affecting over 5 million patients globally, with Ulcerative Colitis (UC) and Crohn’s Disease (CD) being the most common types. Both UC and CD are characterised by chronic intestinal inflammation leading to long term discomfort and disability. IBD often develops in early adulthood and significantly affects quality of life.

Currently available drugs to treat IBD are largely non-specific to the area requiring treatment, resulting in serious side effects and with limited efficacy. Moreover, many are injectable and can only be administered in hospitals.

CHAIN’s novel treatment is targeted to the gut and taken orally at the patient’s convenience. It offers significant cost savings over existing drug options. The treatment is suitable for long term use and may also be used alongside current treatments to reduce relapse and the need for steroids, immunosuppressants or surgery.

CHAIN’s live biotherapeutic product delivers bioactives directly into the colon and is a promising new treatment for IBD and is also being investigated for use in targeting Colorectal Cancer. CHAIN has demonstrated efficacy using intestinal organoids developed using endoderm stem cell biology.